FGL1 inhibited CD8+ T and NK cell functions via its receptor LAG-3, explaining to some extent why the liver has high susceptibility to primary tumors and is a common site of tumor metastasis and providing a strategy of checkpoint targeting for liver cancer immunotherapy. Here, FGL1 is linked to liver cancer.